Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canagliflozin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canagliflozin Anhydrous SCHEMBL23930431 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL681039 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL322059 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL28454075 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL29358577 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493519 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493514 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL15888791 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16075101 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL24037935 | 0.99 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015158839-A1 | NOVEL CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE | LEK PHARMACEUTICALS D.D. (SI) | 2015-10-22 | — | — | WO | disclosed |
| EP-2590631-A2 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012006298-A2 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |